EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Health-related quality of life after definitive chemoradiotherapy in patients with esophageal carcinoma: a population-based analysis

D Wekking, F H Erdmann, L M Veen, S C Kuijper, M Pape, P S N van Rossum, P M Jeene, K J Neelis, M Slingerland, O Loosveld, T Rozema, M A G Sprangers und 2 weitere

Supportive Care in Cancer · 2026-04 · 34 (4)

DOI: 10.1007/s00520-026-10450-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Supportive Care in Cancer, online erschienen am 10.03.2026. Verfasst von D Wekking und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Quality of Life, Esophageal Neoplasms, Chemoradiotherapy, Adenocarcinoma. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Definitive chemoradiotherapy (dCRT) can achieve durable local control and even cure in patients with locally advanced esophageal cancer. However, survival benefit may be accompanied by a decline in health-related quality of life (HRQoL) owing to experienced adverse effects. This study aims to investigate HRQoL in patients with locally advanced esophageal cancer receiving dCRT in a real-world setting.

Methods

Patients with locally advanced esophageal squamous cell carcinoma or adenocarcinoma receiving dCRT (≥ 50.4 Gy/28 fractions with concomitant weekly chemotherapy) were eligible. Patient-reported outcome measures were prospectively collected using the validated questionnaires EORTC-QLQ-C30 and EORTC-QLQ-OG25 at baseline and every 3 months thereafter for 2 years. Clinical data were obtained from the Netherlands Cancer Registry. Longitudinal HRQoL outcomes were compared to baseline using mixed effect models.

Results

318 patients were included with a median age of 70 years. The total number of available questionnaires across all timepoints was 718. Out of 318 alive patients, 223 (70.1%) returned a questionnaire at baseline, which declined to 71 out of 195 (36.4%) at 2 years. Global health status at baseline was 70.6 (95% CI 68.1–73.1) and remained stable over time. Patients reported significantly lower physical (-13.0), role (-18.9), cognitive (-6.6), and social functioning (-14.4) at 3 months compared to baseline (all p < 0.0001). Social and cognitive functioning scores recovered to baseline level at 6 months. Physical and role functioning, and the symptom scales fatigue and dyspnea, remained impaired until 2 years after baseline. Significant improvements were observed for anxiety, eating restrictions, odynophagia and dysphagia at nearly all time points, but most pronounced at 12 or 18 months.

Conclusions

Our study showed that where global health status remained stable from 6 months after dCRT, the burden of disease-specific symptoms decreased. Social and cognitive functioning first deteriorated but recovered over time, whereas the decline in physical functioning, role functioning, fatigue and dyspnea did not recover to baseline level. These findings can provide valuable insights to address concerns regarding the impact of dCRT on HRQoL within the context of shared decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeEsophageal NeoplasmsChemoradiotherapyAdenocarcinomaEsophageal Squamous Cell CarcinomaHumansFemaleMaleAgedMiddle AgedPatient Reported Outcome MeasuresNetherlandsSurveys and QuestionnairesProspective StudiesAged, 80 and overHealth StatusLongitudinal Studies

Stichwörter der Autor:innen

Definitive chemoradiationEsophageal cancerHealth-related quality of lifeLong-term follow-upPatient-reported outcome

Autor:innen und Institutionen

  • Department of Medical Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.
  • Cancer Treatment and Quality of Life, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Department of Research & Development, Comprehensive Cancer Organisation (IKNL), Utrecht, the Netherlands.
  • Department of Radiation Oncology, Amsterdam UMC Location University of Amsterdam, Amsterdam, the Netherlands.
  • Radiotherapiegroep, Deventer, the Netherlands.
  • Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.

Zitieren

APA

Wekking, D., Erdmann, F. H., Veen, L. M., Kuijper, S. C., Pape, M., van Rossum, P. S. N., Jeene, P. M., Neelis, K. J., Slingerland, M., Loosveld, O., Rozema, T., Sprangers, M. A. G., Verhoeven, R. H. A., & van Laarhoven, H. W. M. (2026). Health-related quality of life after definitive chemoradiotherapy in patients with esophageal carcinoma: a population-based analysis. Supportive Care in Cancer, 34(4). https://doi.org/10.1007/s00520-026-10450-2

Vancouver

Wekking D, Erdmann FH, Veen LM, Kuijper SC, Pape M, van Rossum PSN, et al. Health-related quality of life after definitive chemoradiotherapy in patients with esophageal carcinoma: a population-based analysis. Supportive Care in Cancer. 2026;34(4). doi:10.1007/s00520-026-10450-2

BibTeX
@article{Wekking2026,
  author = {Wekking, D and Erdmann, F H and Veen, L M and Kuijper, S C and Pape, M and van Rossum, P S N and Jeene, P M and Neelis, K J and Slingerland, M and Loosveld, O and Rozema, T and Sprangers, M A G and Verhoeven, R H A and van Laarhoven, H W M},
  title = {Health-related quality of life after definitive chemoradiotherapy in patients with esophageal carcinoma: a population-based analysis},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {4},
  doi = {10.1007/s00520-026-10450-2}
}
Kostenlos starten →